Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2019 | 1 |
2020 | 2 |
2022 | 1 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
J Clin Oncol. 2020 Mar 10;38(8):784-792. doi: 10.1200/JCO.19.01231. Epub 2019 Nov 26.
J Clin Oncol. 2020.
PMID: 31770060
Free article.
Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG). PATIENTS AND METHODS: In the PETHEMA/GEM2012MENOS65 trial, 458 patients with newly diagnosed MM had longitudinal asse …
Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Workin …
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
Lahuerta JJ, Paiva B, Vidriales MB, Cordón L, Cedena MT, Puig N, Martinez-Lopez J, Rosiñol L, Gutierrez NC, Martín-Ramos ML, Oriol A, Teruel AI, Echeveste MA, de Paz R, de Arriba F, Hernandez MT, Palomera L, Martinez R, Martin A, Alegre A, De la Rubia J, Orfao A, Mateos MV, Blade J, San-Miguel JF; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group.
Lahuerta JJ, et al.
J Clin Oncol. 2017 Sep 1;35(25):2900-2910. doi: 10.1200/JCO.2016.69.2517. Epub 2017 May 12.
J Clin Oncol. 2017.
PMID: 28498784
Free PMC article.
Patients and Methods Data were analyzed from 609 patients who were enrolled in the GEM (Grupo Espanol de Mieloma) 2000 and GEM2005MENOS65 studies for transplant-eligible MM and the GEM2010MAS65 clinical trial for elderly patients with MM who had …
Patients and Methods Data were analyzed from 609 patients who were enrolled in the GEM (Grupo Espanol de Miel …
Item in Clipboard
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.
Encinas C, Hernandez-Rivas JÁ, Oriol A, Rosiñol L, Blanchard MJ, Bellón JM, García-Sanz R, de la Rubia J, de la Guía AL, Jímenez-Ubieto A, Jarque I, Iñigo B, Dourdil V, de Arriba F, Pérez-Ávila CC, Gonzalez Y, Hernández MT, Bargay J, Granell M, Rodríguez-Otero P, Silvent M, Cabrera C, Rios R, Alegre A, Gironella M, Gonzalez MS, Sureda A, Sampol A, Ocio EM, Krsnik I, García A, García-Mateo A, Soler JA, Martín J, Arguiñano JM, Mateos MV, Bladé J, San-Miguel JF, Lahuerta JJ, Martínez-López J; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group.
Encinas C, et al.
Blood Cancer J. 2022 Apr 19;12(4):68. doi: 10.1038/s41408-022-00652-2.
Blood Cancer J. 2022.
PMID: 35440057
Free PMC article.
Item in Clipboard
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.
Garcés JJ, Bretones G, Burgos L, Valdes-Mas R, Puig N, Cedena MT, Alignani D, Rodriguez I, Puente DÁ, Álvarez MG, Goicoechea I, Rodriguez S, Calasanz MJ, Agirre X, Flores-Montero J, Sanoja-Flores L, Rodriguez-Otero P, Rios R, Martinez-Lopez J, Millacoy P, Palomera L, Del Orbe R, Pérez-Montaña A, El Omri H, Prosper F, Mateos MV, Rosiñol L, Blade J, Lahuerta JJ, Orfao A, Lopez-Otin C, San Miguel JF, Paiva B; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group.
Garcés JJ, et al.
Leukemia. 2020 Nov;34(11):3007-3018. doi: 10.1038/s41375-020-0883-0. Epub 2020 Jun 1.
Leukemia. 2020.
PMID: 32475991
Item in Clipboard
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosiñol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, Hernandez MT, Lopez-Jimenez J, Ocio EM, Puig N, Paiva B, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group.
Medina-Herrera A, et al.
Blood Cancer J. 2024 Apr 29;14(1):74. doi: 10.1038/s41408-024-01053-3.
Blood Cancer J. 2024.
PMID: 38684670
Free PMC article.
Clinical Trial.
For this reason, we carried out next-generation sequencing and fluorescent in-situ hybridization studies on 57 HR and ultra-high risk (UHR) SMM patients treated in the phase II GEM-CESAR clinical trial (NCT02415413). DIS3, FAM46C, and FGFR3 mutations, as well as t(4;14) an …
For this reason, we carried out next-generation sequencing and fluorescent in-situ hybridization studies on 57 HR and ultra-high risk (UHR) …
Item in Clipboard
Cite
Cite